Chapter 33 - Diabetes Mellitus - d2ogjlfjkptkow.cloudfront.net · Diabetes is largely preventable. The principles of preven - tative management apply a holistic therapeutic approach

334

Type 2 diabetes mellitus represents a global epidemic that is predicted to intensify. The number of individuals with type 2 diabetes mellitus (DM) worldwide was 30 million in 1985, 171 million in 2000, and 220 million in 2009.1 As of 2014, type 2 DM is estimated to affect 387 million individ-uals worldwide,2 representing a worldwide prevalence of 8.3%. From 1990 to 2008, the prevalence of DM doubled, and had not declined by 2012.3 From 1998 to 2009, the prevalence of DM rose a staggering 230% in Canada alone and is predicted to continue rising. The CDC estimates 40% of Americans will develop DM in their lifetime.4

Type 2 DM is common in both the developed and developing worlds.5,6 The increasing prevalence of DM is attributed to rising obesity rates, sedentary lifestyles, aging populations, and improved survival of individuals with the disease.7

Type 2 DM is also associated with huge health care costs. In a special report from 2009 entitled, An Economic Tsunami: the Cost of Diabetes in Canada, the estimated cost of type 2 DM in 2010 was $12.2 billion and projected to increase by a further $4.7 billion by 2020.8

The silver lining is that type 2 DM is largely prevent-able, with epidemiological studies predicting primary prevention of diabetes in America could reduce the risk of all-cause and cardiovascular mortality by up to 9.0%.9

PATHOPHYSIOLOGY

The pathophysiology of type 2 DM is complex and fun-damentally consists of hyperglycemia, insulin resistance, and impaired insulin secretion4 (see Fig. 33.1 for a gen-eral overview).

Carbohydrate intake and subsequent absorption of glucose into the blood triggers insulin release from the beta cells of the pancreas. Insulin stimulates the uptake of glucose into cells via the GLUT-4 glucose transporter. Insulin resistance (IR) may ensue after chronic exposure to high serum glucose levels. Steroid administration and physical inactivity may also contribute.10 The develop-ment of type 2 DM is thought to be characterized by peripheral cells becoming unable to efficiently uptake glucose in response to insulin in combination with beta islet cell dysfunction and decreased insulin production.

Insulin functions in stimulating cellular glucose uptake, decreasing hepatic gluconeogenesis, and increas-ing adipose tissue triglyceride synthesis, glucagon regu-lation, and vascular tone. These important functions of insulin are all impaired in type 2 DM.

Diabetes is referred to as “starving amidst the feast.” IR refers to impaired glucose transport into muscle cells that accounts for the “starving” amidst the hyperglycemia

“feast.” Additionally, cellular starvation feedback mecha-nisms exacerbate hyperglycemia by stimulating hepatic gluconeogenesis and fat breakdown.

IR also contributes to the production of free fatty acids and inflammatory cytokines. Inflammatory markers shown to be elevated in DM include C-reactive protein, IL-6, plas-minogen activator inhibitor-1 (PAI-1), and tumor necrosis factor (TNF)-alpha, in addition to white cell count.11-13

Adiponectin is an antiinflammatory cytokine that has been shown to reduce plasma levels of free fatty acids. High adiponectin is associated with improved lipid pro-files, glycemic control, and reduced inflammation.14 DM has shown to be correlated with a reduction in adiponectin.15

Adiponectin is a hormonal protein produced by adipose tis-sue. Contrary to common sense, low levels (not high) of adi-ponectin are bad and result from a proinflammatory state. Ad-iponectin levels can be increased with exercise and weight loss.

While studies on type 2 DM pathophysiology have previously focused on IR, the role of the pancreas has become increasingly recognized. Beta islet cells are well known to produce insulin; however, these are not the only pancreatic islet cells. Alpha islet cells produce gluca-gon, considered a counterpart of insulin. The interaction between insulin and glucagon is usually very tightly regu-lated; however, increased glucagon further exacerbates the hyperglycemic state in type 2 DM as a result of IR and impaired insulin secretion.16

Genetics also contribute to the pathogenesis of type 2 DM. Medical genomics is considered to be a field of active research with great potential. Genomic single-nucleotide polymorphisms (SNPs) have been shown to be associated with DM risk.17-20 Genetic risk may also interact with environmental factors.

Inorganic arsenic exposure in drinking water increases risk of type 2 DM.21 Bisphenol A, used in hard plastics and resins, has also been linked to DM.22 Pesticide expo-sure, specifically organophosphates and chlorinated pes-ticides, may also be associated with increased risk.23

INTEGRATIVE THERAPY

LifestyleDiabetes is largely preventable. The principles of preven-tative management apply a holistic therapeutic approach to patients with established DM.

C H A P T E R 3 3

Diabetes MellitusMatthew Moher, MD

Downloaded for Aman Shah ([email protected]) at Elsevier - Demonstration Account from ClinicalKey.com by Elsevier on December 21, 2017.For personal use only. No other uses without permission. Copyright ©2017. Elsevier Inc. All rights reserved.

33 Diabetes Mellitus 335

Four large epidemiological, long-term studies are widely cited in support of lifestyle intervention as the cornerstone of type 2 DM prevention.

In 2001, the Finnish Diabetes Prevention Study (DPS) investigated 522 middle-aged, overweight sub-jects with impaired glucose tolerance over 4–10 years. The lifestyle intervention consisted of counseling aimed at reducing weight, total intake of fat, and intake of saturated fat, and increasing intake of fiber and physical activity. Annual oral glucose tolerance testing indicated DM to be largely preventable in this cohort of high-risk individuals.24

In 2002, the Diabetes Prevention Program (DPP) investigated 3234 overweight high-risk individuals with impaired glucose intolerance (mean age, 51 years) over a 3-year period. Similar lifestyle interventions to the Finnish study were found to be superior to metformin in terms of diabetic prevention.25

The China Da Qing Diabetes Prevention Study, involving 577 high-risk individuals identified by a region-wide clinic screening process of >110,000 indi-viduals, reported similar results over 6 years of lifestyle intervention.26

More recently, the 2011 nationwide Zensharen Study for Prevention of Lifestyle Diseases involving 641 over-weight Japanese middle-aged persons with impaired glu-cose tolerance reported lifestyle modifications regarding weight loss, diet scrutiny, and exercise were associated with a decreased risk of type 2 DM.27

SmokingSeveral studies, including meta-analyses, have shown smoking is a preventable risk factor for type 2 DM.28,29 Mechanisms underlying the association between smok-ing and type 2 DM include impaired insulin sensitivity, glucose tolerance, and the metabolic syndrome.

ExerciseExercise is tantamount in both the prevention and man-agement of type 2 DM. Large cohort studies over 15–20 years have reported decreased cardiovascular risk and all-cause mortality in diabetics who undertake regular physical activity.30-32 Both aerobic exercise and resistance training reduce HbA1c in patients with type 2 DM.33

Studies indicate regular yoga can reduce HbA1c and fasting blood glucose levels. Hatha yoga is reported to have most evidence in reviews. In fact, Hatha yoga has shown to reduce HbA1c to the same effect as regular aerobic exercise.34,35

Health care providers can support patients by encour-aging 30 to 60 minutes of moderate-intensity aerobic activity on most days of the week. The American Heart Association, the American Diabetes Association, and the American College of Sports Medicine recommend at least 150 minutes of moderate-intensity aerobic activity per week for patients with diabetes36 (see Chapter 91, Writing an Exercise Prescription).

NutritionNutrition, exercise, and lifestyle are the tripartite corner-stones of integrative diabetic management. Evidence sup-ports the use of all three of these important modalities.

Nutrition therapy alone has been shown to improve glycemic control and lower HbA1c levels by 1%–2%.37,38 This powerful evidence comes from multidisciplinary efforts between general practitioners, registered dietitians, and educators to individualize diet plans with regular fol-low-up. Dietitians and diabetic nurse educators are valu-able resources with clear benefit in DM management.39-41

In general, diets incorporating the principles of food guides, such as the Healing Foods Pyramid (Fig. 33.2), are a good starting point for clinicians and patients.

Chronic inflammationand oxidative stress

Cardiovascular disease

Endothelialdysfunction

Plateletactivation

T2DM Hypertension Dyslipidemia

Toxins, emotional stress, infection, diet, lifestyle, genetic factors

FIG. 33.1 □ Pathophysiology of type 2 diabetes mellitus and inflammatory disorders. T2DM, type 2 diabetes mellitus.


PART II IntegratIve approach to DIsease336

Education regarding glycemic index (GI) takes this approach a step further. Glycemic index refers to blood glucose spikes following the intake of certain foods. High GI foods, such as table sugar, have greater effects on blood glucose levels and generate wide swings in insu-lin levels, eventually contributing to IR. A large multi-center meta-analysis demonstrated that diets containing low GI foods can reduce HbA1c by 0.43%.42 GI tables are widely available online (http://www.diabetes.ca/dia-betes-and-you/healthy-living-resources/diet-nutrition/the-glycemic-index).

Another important concept is glycemic load (GL). GL is based on GI but also incorporates the quantity of car-bohydrate in a typical serving size. For example, bananas have a low GI (52) but a high GL (10.5) due to high car-bohydrate content by weight). Conversely, watermelon has a high GI (72) but low GL (3.6) (see Chapter 87).

Specific FoodsFiber

Soluble dietary fibers, such as psyllium, oats, beans, and eggplant, have been shown to lower postprandial blood glucose.43 Pulses, such as lentils, chickpeas, and beans, also lower blood glucose.44 Soy, walnuts, and other nuts have

demonstrated similar benefits.45-47 Almonds in particular have been shown to reduce both HbA1c and postprandial blood glucose levels in small trials.48,49 A growing body of research supports the beneficial effects of vegetarian and vegan diets for patients with type 2 DM.50-52 In addi-tion to vegetable protein, whole grains are also rich in minerals and antioxidants. In a large prospective cohort study, fiber from whole grains improved glycemic control in patients with type 2 DM.53

Alcohol

Light to moderate alcohol consumption may be benefi-cial in DM. Studies have shown decreased risk of type 2 DM and death due to CAD in established diabetics.54 The majority of studies included in this review favored red wine, indicating the antioxidant effects of resveratrol to be a potential mechanism. Further, moderate alcohol consumption has been linked with higher adiponectin levels. Adiponectin, described previously, supports glu-cose homeostasis and improves insulin sensitivity.

The resveratrol and alcohol in red wine may raise adiponec-tin levels and maintain insulin sensitivity.

MISO

Healing Foods Pyramid

Accompaniments

Lean MeatsAdapted fromUniversity of MichiganIntegrative Medicine

http://www.med.umich.edu/umim

Fish and Seafood

Eggs

Seasonings

Vegetables

Water

Healthy Fats

Legumes

Grains

Dairy

Optional

Weekly

Daily

Fruits

FIG. 33.2 □ University of Michigan integrative medicine health foods pyramid. (Reproduced from Regents of the University of Michigan. Developed by Monica Myklebust, MD, and Jenna Wunder, MPH, DR, 2008.)


http://www.diabetes.ca/diabetes-and-you/healthy-living-resources/diet-nutrition/the-glycemic-index




Dietary Fat

Diets higher in saturated versus polyunsaturated fats have been shown to be associated with increased HbA1c and IR in patients with type 2 DM.55 The quality of fat is impor-tant. Research supports selective fat intake, favoring mono-unsaturated and polyunsaturated fats such as omega-3, which have been shown to prevent cardiovascular disease.

The Mediterranean diet captures the beneficial effects of macronutrient selectivity. A rigorous 4-year trial and subsequent 8-year follow-up comparing a low carbohy-drate Mediterranean diet versus a low fat diet reported a reduction in HbA1c, decreased requirement for the ini-tiation of diabetes medications, and an increase in cases of diabetes remission.56,57

Other foods that may be of benefit include chia (Salvia hispanica), which is rich in alpha-linoleic acid, and onions (Allium cepa). Magnesium deficiency has been shown to be a risk factor for type 2 DM.58 Magnesium is found in dark green leafy vegetables, nuts, whole grains, and coffee. Moderate caffeine intake in the form of coffee or green tea may decrease risk of type DM according to a systematic literature review and meta-analysis.59

Mind-Body TherapyMindfulness

A plethora of literature is amassing in support of the health benefits of mindfulness, with 52 papers published in 2003, rising to 477 by 2012. Nearly 100 randomized controlled trials (RCTs) of mindfulness were published in 2014. Mind-fulness has been shown to reduce stress, blood pressure, and even mitigate cardiovascular risk. A particularly interesting study involving PET scans of Buddhist monk brains during meditation provided concrete evidence that meditation can induce neurophysiological changes60 (see Chapter 100).

Cognitive-Behavioral Therapy

Cognitive-behavioral therapy helps patients gain insight into the habits and patterns that affect their thoughts and actions and the ways in which these thoughts and actions affect their health and lives. A sizeable body of research has established the benefits of cognitive-behavioral ther-apy on glycemic control and self-care. In a systematic review of 25 trials in type 2 DM, 12 trials involving 522 patients used glycemic control as an outcome measure. In those trials, participants who received 6 to 16 group or individual counseling sessions had s 0.76% reduction in HbA1c levels compared to placebo.61,62

Biofeedback

Biofeedback training can strengthen the mind-body con-nection by helping patients learn to control specific bodily functions, including muscle tension, skin temperature, sweating, breathing, heart rate, and even regional brain waves. In a published study, researchers randomized 39 patients with well-controlled type 2 DM to receive 10 weekly individual sessions of skin temperature and electro-myograph biofeedback or 3 group education sessions. Bio-feedback was associated with improved glycemic control

and a decrease in HbA1c levels by 0.8%.63 This finding may seem surprising; however, biofeedback trials have reported changes in plasma cortisol, peripheral vasoconstriction, and other markers of sympathetic nervous system activity.

Sleep Hygiene

Several studies have linked poor sleep hygiene with DM risk. Systematic and meta-analyses of these studies have confirmed that too short, too long, or interrupted sleep compared to 8 hours of uninterrupted sleep significantly increases DM risk.64

Herbalism

Herbalism is the most ancient practice of medicine, indeed as old as human beings. Even chimpanzees have been shown to use plant medicines for the treatment of certain gastrointestinal ailments.

As an example, metformin, a derivative of the French lilac, has been used to treat DM since the middle ages.

Personally, I advise consultation with professional herbalists, preferably registered under their respective regional guild, to ensure prescription quality. In general, I value tincture extracts more than capsules of ground material due to greater potency and bioavailability. For patients who prefer over-the-counter medications or are unable to afford a herbalist consultation, I would recom-mend the use of products that are standardized extracts.

Table 33.1 includes a review of literature regarding commonly used plants and supplements. Below are plant medicines that have been trialed for at least 3 months (the lifespan of a RBC is 120 days) and demonstrated reduc-tions in HbA1c levels of at least 0.5% in patients with type 2 DM.

BotanicalsCoccinia cordifolia

Coccinia cordifolia, or ivy gourd, is a perennial herb of the cucumber family. It is native to India but spreads eas-ily and is now distributed worldwide. It is an important Ayurvedic diabetes medicine with additional choleretic, laxative, antiinflammatory, and demulcent properties. The leaves appear to have insulinomimetic effects on lipo-protein lipase, glucose-6-phosphatase, and other glyco-lytic enzymes. A double-blind, placebo-controlled RCT of 60 diabetics aged 35–60 years was performed, with the treatment arm consisting of 1 g ivy gourd extract for 90 days. The results demonstrated significant decreases in fasting, postprandial blood glucose, and HbA1c levels compared to placebo.65

DosageDried leaves or extracts at doses equivalent to 15 g can be taken with meals.

PrecautionsIvy gourd is well-tolerated but may cause nausea, drowsi-ness, and headaches.



TABLE 33.1 Glycemic Effects and Cardiovascular Benefits of Different Treatments for Type 2 Diabetes Mellitus

Therapy Effects Cardiovascular Benefits

Arsenic exposure avoidance Arsenic exposure increased risk by 358% in population studies

—

Emotional stress avoidance Emotional stress increased risk by 60% to 236% in population studies

CV and all-cause mortality

Egg avoidance Egg consumption increased risk by 50% in two population studies

CV disease

Coffee Reduced risk by 40% in meta-analysis Lipids, CV mortality

Leafy green vegetables Reduced risk by 14% in meta-analysis BP, lipids, all-cause mortality

Moderate alcohol consumption Reduced risk by 50% in meta-analysis Lipids, CV and all-cause mortality

Avoidance of sugar-sweetened beverages

Sugar-sweetened beverages increased risk by 26% in meta-analysis

—

Treatment of periodontal disease Periodontal disease increased risk by 150% to 225% in population studies

MI and stroke risk

Lifestyle intervention HbA1c decreased 0.3% in meta-analysis BP, lipids

Regular exercise HbA1c decreased 0.6% in meta-analysis BP, lipids, CV and all-cause mortality

Low-glycemic diet HbA1c decreased 0.5% in meta-analysis Lipids, CV disease

Beans and pulses HbA1c decreased 0.5% in meta-analysis BP, lipids

Chia — BP, C-reactive protein

Cognitive-behavioral therapy HbA1c decreased 0.78% in meta-analysis —

Biofeedback HbA1c decreased 0.8% in one trial —

Treatment of vitamin D deficiency May decrease type 2 DM risk Endothelial function

Chromium HbA1c decreased 0.6% in meta-analysis —

Alpha-lipoic acid Decreased diabetic neuropathy ? Liver, CV disease

Omega-3 fatty acids — Lipids, platelets, CV disease

Magnesium HbA1c decreased 0.3% in meta-analysisReduces type 2 DM risk 16%

Lipids, endothelial function

l-Carnitine ? Insulin sensitivity Lipids, lipoprotein(a)

Benfotiamine Endothelial function

Vitamin K2 ? Stimulates beta cells CV disease

Avoidance of selenium Selenium may increase risk 55% —

Avoidance of high-dose vitamin B6, vitamin B12, folate

These vitamins may increase nephropathy Increased CV disease

Berberine HbA1c decreased 0.9% in one trial —

Cinnamon HbA1c decreased 0.5% in one trial —

Ginseng Improved glucose parameters —

Fenugreek HbA1c decreased 1.4% in one trial —

Ivy gourd HbA1c decreased 0.6% in one trial —

Momordica charantia Improved glucose parameters in four trials —

Prickly pear cactus stem Improved glucose parameters in one trial —

Pycnogenol HbA1c decreased 0.8% in one trial —

Metformin HbA1c decreased 1.0% CV and all-cause mortality

Sitagliptin HbA1c decreased 1.25% —

Sulfonylurea HbA1c decreased 1.0% May increase risk

Pioglitazone HbA1c decreased 1.25% —

Bariatric surgery Curative in 78% of patients ? CV and all-cause mortalityInsulin Dose-dependent —

BP, blood pressure; CV, cardiovascular; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; MI, myocardial infarction.



Salacia Reticulate

Salacia reticulate, or kothala himbutu, was investigated in a double-blind, crossover RCT of an herbal tea contain-ing kothala himbutu extract in 51 patients with controlled DM over 3 months. This study reported significantly lower HbA1c levels in the treatment arm.66

DosageThree times daily before meals. In the previous trial, the tea was manufactured by Siddhalepa Ayurveda Hospitals, Rat-malana, Sri Lanka and prepared in accordance with a pat-ented formula (international patent application no. PCT/IB00/00405).

PrecautionsSide effects are dose-dependent and predominantly include gastrointestinal disturbances, such as gas, bloating, abdomi-nal pain, and diarrhea.

Touchi (Soy)

Water-extracted touchi, a traditional Chinese food (soy-bean extract), has been shown to exert a strong inhibitory effect on rat intestinal alpha-glucosidase. Touchi was also investigated in a 3-month, double-blind, randomized trial of 36 diabetics. Treatment consisted of 0.3 g of touchi in the form of tea preprandially for 3 months and resulted in a reduction in HbA1c levels by 0.5% vs placebo.67

Dosage0.3 g in tea before meals.

PrecautionsWell tolerated orally but may cause mild gastrointestinal upset.

Gynostemma Pentaphyllum

Gynostemma pentaphyllum is a Vietnamese herb used as a tea to treat DM. A double-blinded RCT of 24 drug-naïve patients with diabetes treated with 6 g tea daily for 12 weeks vs placebo reported a reduction in plasma glucose and a decrease in HbA1c levels of 2%.68

Dosage6 g in tea daily.

PrecautionsGenerally well tolerated but may cause nausea and diarrhea.

Marine Collagen Peptides (Gelatin)

Marine collagen peptides from fish hydrolysate, a tradi-tional Chinese medicine, were investigated in an RCT of 100 patients with diabetes compared to a control group. This trail reported that administration of 13 g of marine collagen peptides for 3 months significantly low-ered LDL, free fatty acids, and markers of inflammation, such as C-reactive protein and nitric oxide, in addition

to reducing HbA1c levels and increasing adiponectin levels.69

Dosage13 g as a capsule daily.

PrecautionsMay cause an unpleasant taste, bloating, gas, or heaviness in the stomach.

Silymarin (Milk Thistle)

The antioxidant flavonoid silymarin, an extract of milk thistle (Silybum marianum), has demonstrated good results in several rigorous trials. As an adjunct to gliben-clamide, silymarin was investigated at a dose of 200 g/day in 52 patients with diabetes for 120 days. This random-ized, placebo-controlled, double-blinded trial reported reductions in HbA1c levels and body-mass index.70,71

Dosage200 g/day extract.

PrecautionsWell tolerated but may have a laxative effect or cause gastro-intestinal symptoms.

Citrullus Colocynthis

Citrullus colocynthis, also known as the schrad fruit, is a tra-ditional medicine of Iran. A clinical trial investigating 25 patients with diabetes treated with 100 mg fruit capsules versus control reported significant reductions in plasma glucose and HbA1c levels.72

Dosage100 mg fruit capsules.

PrecautionsHigh doses may cause irritation of the gastric mucosa result-ing in bloody diarrhea and colitis. Nephrotoxicity has also been documented.

Cinnamon

Cinnamon is a culinary spice made from the bark of Cinnamomum sp. trees. The aqueous extract appears to improve insulin receptor function by multiple mecha-nisms in addition to increasing glycogen synthase activity. However, the results of clinical trials have been incon-sistent, with the majority of trials being small and insuf-ficiently powered. A proportion of trials have reported the benefit of cinnamon in reducing HbA1c levels.73 A trial compared Cinnamomum aromaticum (cassia cinna-mon) 500 mg twice daily with usual care in 109 patients with type 2 DM for 90 days. This trial reported mean reductions in HbA1c levels of 0.83% in the cinnamon group and 0.37% in those receiving usual care, a differ-ence that reached statistical significance.74 A Cochrane



meta-analysis of 10 RCTs did not demonstrate the effi-cacy of 2-g Cinnamomum cassia in reducing HbA1c lev-els.75 However, a separate meta-analysis concluded that cinnamon can reduce plasma blood glucose levels.76 More investigation is required regarding this.

DosageThe optimal dose of cinnamon for the treatment of type 2 DM is unclear; however, 1- to 2-g doses are commonly prescribed (1 teaspoon of cinnamon is equivalent to 4.75 g). The majority of over-the-counter cinnamon preparation are a combination of cassia and Ceylon cinnamon.

PrecautionsStomatitis and perioral dermatitis have been reported with the use of cinnamon.

Fenugreek

Trigonellafoenum graecum, or fenugreek, is a legume used extensively in India, North Africa, and the Mediterranean. The defatted seeds of fenugreek have been used to treat diabetes for centuries in Ayurvedic and other healing sys-tems. A component of fenugreek, 4-hydroxyisoleucine, has been shown to increase pancreatic insulin secretion and inhibit glucosidase activity, with studies reporting effects on satiety, gastric emptying, and insulin receptor function. Fenugreek may also have lipid-lowering effects and several studies have posited hypoglycemic effects. In 42 patients with diabetes poorly controlled with sulfonyl-ureas, 2.1 g fenugreek extract tid for 12 weeks reduced HbA1c and fasting blood glucose levels compared to placebo.77

DosageUntil further evidence provides clear guidance, practitioners may use crude powder or extracts at doses equivalent to 20 to 30 g of crude seeds. This dose can be titrated according to meal size and individual results.

PrecautionsFenugreek may cause gastrointestinal intolerance, with diar-rhea, dyspepsia, abdominal distention, and flatulence.

SupplementsTable 33.1 describes the glycemic effects and cardiovas-cular benefits of different treatments for type 2 DM.

Vitamin D

25(OH)D levels have been shown to be lower in type 2 DM and obesity. Studies have reported that vitamin D levels are associated with increased risk of type 2 DM, by virtue of insulin sensitivity and beta cell activ-ity. However, while studies are supportive of the use of vitamin D supplementation in the management of type 2 diabetes, others remain inconclusive. A review of eight trials reported no glycemic benefit of vitamin D supplementation.78

Chromium

This trace element has several effects on carbohydrate and lipid metabolism. A complex containing trivalent chromium has been shown to influence glucose toler-ance. Evidence suggests that chromium acts to reduce tissue lipid content and that chromium responders are more likely to be more obese, more insulin resistant, and have poorer glycemic control regardless of baseline chromium status.74 A meta-analysis of 41 trials evaluating the glycemic effects of various formulations identified 14 trials of chromium including patients with type 2 DM.75 However, the evidence was determined to be difficult to interpret because of low study quality and differences in formulation and dose, with the best results reported by trials evaluating chromium picolinate or brewer’s yeast at doses of at least 200 mcg daily. In these trials, a mean reduction in HbA1c of 0.6% compared with placebo was reported.

DosageA dose of 200 to 1000 mcg daily is recommended.

PrecautionsChromium has no known side effects.

Alpha-Lipoic Acid

Also known as thioctic acid, alpha-lipoic acid (ALA) is a potent lipophilic antioxidant that is found in most eukaryotic cells. ALA also acts as a cofactor for several mitochondrial and cytosolic enzymes, with the right-sided enantiomer being the active form. In addition to its antioxidant activity, ALA can also regenerate other antioxidants via reduction reactions, including vitamins C and E, coenzyme Q10, and glutathione. ALA also che-lates mercury, arsenic, iron, and other metals that act as free radicals. ALA is present in trace amounts in organ meats and some vegetables, but these amounts are negli-gible compared with usual therapeutic doses.

ALA has been used to treat several diseases in Europe and Japan since the 1950s. A large body of preclinical research supports the potential benefit of ALA in liver disorders, cardiovascular disease, cancer prevention, and neuropsychiatric disorders, and for heavy metal and gen-eral detoxification.

Good evidence indicates that ALA reduces painful diabetic neuropathy. First used parenterally, ALA in oral form has been shown to be effective in a multicenter trial involving 181 patients with type 2 DM who received varying doses for 5 weeks. All doses provided an overall reduction in symptoms of 50%, with the lowest dose (600 mg daily) causing the fewest side effects.76 This finding may be related to reduced lipid peroxidation in neuro-nal cell membranes or improved endothelial function and microvascular blood flow.77 ALA may also improve insulin sensitivity through enhanced GLUT4 transloca-tion and glucose uptake in muscle and fat cells.78 This last effect was observed by trials of intravenous ALA and has yet to be firmly established with the oral form; however,



this study provides further support for the use of ALA in patients with type 2 DM.

The majority of published trials have used regular ALA (an R-S racemic mixture). R-Lipoic acid is marketed as a superior product because it is the endogenously produced form; however, there is a lack of evidence from clinical trials to support this claim. A sustained-release form of ALA is marketed as superior based on the short half-life of regular ALA; however, data to indicate whether peak or total levels are most important, and evidence of the safety and efficacy of this product are similarly lacking. At this time, regular ALA is the only recommended form.

DosageThe most appropriate dose for neuropathy is 600 mg daily; however, a dose of 50 to 100 mg is sufficient for antioxidant purposes. Absorption is greatest on an empty stomach.

PrecautionsThe most common side effect of ALA is nausea; however, in-somnia, fatigue, diarrhea, and rashes have also been reported.

Omega-3 Fatty Acids

Fish and other marine species are the main sources of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the human diet. Alpha-linoleic acid is an omega-3 precursor found in walnuts, flax, and other grains. Although omega-3 fatty acids have no effect on glycemic control, these fats have antiinflammatory, anti-thrombotic, and antiarrhythmic effects that appear to prevent and treat cardiovascular disease. For this reason, omega-3 fatty acids offer important benefits to patients with type 2 DM.

A Cochrane systematic review of 23 trials involving 1075 patients who used omega-3 fatty acids at an aver-age dose of 3.5 g daily reported improved lipid param-eters and platelet function.79 Small trials have reported improvements in endothelial function, with one study reporting significant improvements in impaired flow-mediated dilatation with the consumption of 2 g of omega-3 fatty acids.80

DosageThe majority of cardiovascular benefits of omega-3 fats oc-cur at doses of 1000 mg (EPA and DHA) daily; however, higher doses are often used.

PrecautionsFishy repeats and mild gastrointestinal upset are the only side effects of omega-3 fatty acid supplementation. Although bleed-ing in aspirin or warfarin users is often cited as a reason for caution, the literature contains no specific reports of this effect.

Magnesium

Magnesium affects insulin secretion and action in addi-tion to influencing lipid parameters and endothelial function. A systematic review identified nine trials that

evaluated magnesium supplementation for 4 to 16 weeks in 370 patients with type 2 DM and noted improvements in fasting glucose and high-density lipoprotein choles-terol. In the five trials of sufficient duration to evaluate HbA1c, a nonsignificant reduction of 0.31% (95% CI, −0.81 to 0.19) was reported.81 A separate review of mag-nesium for the prevention of type 2 DM found seven cohort studies and reported an overall benefit, with an average daily dose of 100 mg decreasing the risk of type 2 DM by approximately 16%.82 The accuracy of routine tests in reflecting total magnesium body stores remains unclear.

DosageUsual starting doses are approximately 100 mg daily and can be increased as desired or to bowel tolerance. Magnesium is available as oral liquid or tablets, transdermal lotion, or Epsom salts, as well as in parenteral formulations.

PrecautionsGastrointestinal intolerance, mainly diarrhea, is the most common side effect. Chelated magnesium (magnesium glyci-nate) causes less diarrhea than do other forms of magnesium.

Antioxidants

Individuals who consume diets rich in antioxidants are at greatly reduced risk of type 2 DM; however, commonly-used antioxidant supplements do not appear to have the same preventive effect. In 8171 women who were fol-lowed for 9.2 years in the Women’s Antioxidant Cardio-vascular Study, only a mild benefit of vitamin C in the prevention of type 2 DM was indicated by a nonsignifi-cant trend, whereas vitamin E increased the risk of type 2 DM and beta-carotene offered no benefit.83 The Pre-vention of Progression of Arterial Disease and Diabetes (POPADAD) trial reported no significant benefit in 1276 Scottish adults administered a low-dose mixed antioxi-dant supplement or placebo for 8 years.84

The benefits of antioxidant-rich foods are likely attrib-utable to the dozens of phytomedicines they contain, com-ponents that are currently poorly understood. Although antioxidants and multivitamins are commonly prescribed by integrative practitioners as “insurance against defi-ciency,” this practice may not be safe. High doses of vita-mins have been shown to interfere with absorption and use of lesser-known but potentially more powerful anti-oxidants in food. High profile examples include tocoph-erols and carotenoids. Whole food supplements may be a reasonable alternative approach. In one study, an antioxi-dant supplement derived from pomegranate, green tea, and ascorbic acid improved lipid parameters and markers of oxidative stress in a placebo-controlled trial involving 114 patients with type 2 DM conducted in Turkey.85

Vitamin E

Vitamin E is one of the most commonly used specific anti-oxidants; however, there is a lack of evidence to support its use in patients with type 2 DM. Negative results reported by large cardiovascular and cancer trials have been the



subject of media reports, controversy, and debate among integrative medicine practitioners. Alpha-tocopherol sup-plementation did not decrease the risk of type 2 DM in the large Alpha-Tocopherol Beta-Carotene (ATBC) can-cer trial,86 and a separate small trial reported prooxidant effects shortly after ingestion of a single 1200-unit dose.87

Although several tocopherols and tocotrienols have vitamin E–like activity, the majority of vitamin E supple-ments contain alpha-tocopherol only. Some investigators have posited that the negative results of vitamin E trials are attributable to decreased absorption of other, more potent molecules of this family whose absorption is inhib-ited by alpha-tocopherol supplementation.88 In fact, one study found no difference between the effects of alpha-and gamma-tocopherol on markers of oxidative stress and inflammation in patients with type 2 DM.89 Other trials have reported that gamma-tocopherol increases blood pressure90 and has no effect on platelet function.91

Greater benefit from alpha-tocopherol has been demonstrated among individuals who are homozygous for a haptoglobin gene variant that has been shown to increase oxidative stress and is present in 3% to 4% of the population. In an Israeli double-blind study involv-ing 1434 people with type 2 DM who were homozygous for haptoglobin-2, alpha-tocopherol reduced the risk of a combined cardiovascular end point by more than 50%.92 This is an example of how genetics may improve future treatment outcomes in personalized medicine.

Vitamin E supplements containing mixed tocopher-ols and trienols are increasingly available; however, clear dosing guidelines for their use for type 2 DM have yet to be published. Vitamin E has no known side effects.

L-Carnitine

L-Carnitine shuttles fatty acids into mitochondria and has been proposed as a potential therapy for type 2 DM based on its potential effects on intracellular lipid accumulation. A pilot study found no improvements in glycemic control after 4 weeks of L-carnitine use in 12 patients with type 2 DM;93 however, several trials have reported that L-carni-tine improves lipid parameters and significantly reduces lipoprotein (a), an important independent inherited car-diac risk factor for which few effective therapies exist.94

DosageThe usual dose is 500 to 1000 mg three times daily.

Benfotiamine

Postprandial endothelial dysfunction has been proposed as a link between metabolic syndrome and atherosclero-sis. This state is associated with oxidative stress, hyper-glycemia, hypertriglyceridemia, and altered nitric oxide function, and been attributed to glucose-protein com-plexes in food, named advanced glycation end products (AGEs). These complexes are formed at high tempera-tures and activate AGE-specific receptors, which stim-ulate monocytes and endothelial cells and ultimately promote inflammation.

Benfotiamine is a synthetic analogue of thiamine with significantly greater bioavailability. Benfotiamine acti-vates transketolase, an enzyme that helps clear AGEs, thus improving postprandial endothelial function. In a pilot study, 350 mg of benfotiamine after meals com-pletely eliminated vascular measures of postprandial endothelial dysfunction in 13 patients with type 2 DM.95

This important finding has not been replicated since it was reported in 2006; however, there is a substantial clinical need for corroborating evidence. Several tri-als have indicated that benfotiamine improves diabetic neuropathy,96,97 an unsurprising finding considering the neurological symptoms observed in cases of thiamine deficiency. While one trial reported no improvement in markers of diabetic nephropathy,98 a separate trial reported improvements in microalbuminuria.99

DosageThe 350-mg dose used in the pilot study is higher than found in most formulations.

PrecautionsWhile early evidence is very promising, it is probably prema-ture to recommend the widespread use of synthetic thiamine analogues because long-term safety data are not available.

Vitamin K

This fat-soluble vitamin exists as phylloquinone (K1) in plants, menaquinone (K2) in animals, and a fermented soybean product known as natto. Vitamin K2 is consid-ered more biologically active and is a cofactor for the carboxylation of proteins. Vitamin K2 is involved in the production of osteocalcin, which strengthens bones by forming a protein scaffold. Vitamin K2 is also involved in the production of matrix Gla protein, which prevents vas-cular calcification by repairing smooth muscle and endo-thelium. Vitamin K2 is receiving growing attention as a target for the treatment of diverse disorders in addition to its established role in coagulation factors biosynthesis.

Early studies indicate that vitamin K2 stimulates beta cell proliferation and enhances insulin sensitivity. Vita-min K deficiency, as suggested by low levels of carboxyl-ated osteocalcin, is also associated with an increased risk of type 2 DM.100 Recommending vitamin K2 for glyce-mic control is premature; however, its endothelial and cardiovascular benefits make it an appealing addition to an integrative type 2 treatment plan.

DosageThe starting dose of vitamin K2 is typically 100 mcg daily; however, higher doses have been commonly used.

PrecautionsPatients taking warfarin require close monitoring and dose adjustment after starting vitamin K2; however, vitamin K2 ultimately reduces the fluctuations in international normal-ized ratio observed in vitamin K2-deficient patients.101 Vita-min K has no other known side effects.



Risks of Specific Supplements

Although evidence indicates selenium has insulin-like actions and may delay microvascular complications, integrative practitioners should be aware of the asso-ciation between selenium and the risk of type 2 DM. In the Nutritional Prevention of Cancer trial, 1202 individuals with localized melanoma were randomized to receive selenium or placebo for cancer prevention. After a mean follow-up duration of 7.7 years, sele-nium users developed type 2 DM more often (hazard risk, 1.55; 95% CI, 1.03 to 2.33), with the greatest risk observed in individuals with the highest baseline sele-nium levels (hazard risk, 2.70; 95% CI, 1.30 to 5.61).102 Selenium supplementation should only be considered in patients with low baseline selenium levels. The maxi-mum daily dose is 200 mcg. The mechanisms underly-ing the difference in effects of inorganic and organic forms of selenium on the risk of type 2 DM risk have yet to be elucidated.

Practitioners should exercise caution when using B vitamins in patients with nephropathy. In the Cana-dian Diabetic Intervention with Vitamins to Improve Nephropathy (DIVINe) trial, 238 patients with type 1 DM or type 2 DM were administered a tablet contain-ing folic acid 2.5 mg, vitamin B6 25 mg, and vitamin B12 1 mg daily or placebo for approximately 3 years for the treatment of elevated homocysteine levels. Although the treatment group had lower plasma homocysteine levels, worse kidney function and a higher incidence of car-diovascular events were observed in this group.103 The investigators postulated that this finding may be attribut-able to increased cell proliferation induced by folic acid, increased methylation from folic acid and vitamin B12, or nitric oxide-related mechanisms. Earlier reports noted poorer cardiovascular outcomes associated with B vita-mins, indicating further studies are required to clarify this issue.

PharmaceuticalsThe standard approach to treating type 2 DM is focused on improving glycemic control, as reflected by serum lev-els of HbA1c. This approach is based on the assumption that all reductions in HbA1c are of equal benefit, regard-less of how they are achieved. However, more recent evi-dence contradicts this assumption.

Recent systematic reviews clearly indicate that dif-ferent drugs have different effects on real-world clini-cal measures of morbidity and mortality, independent of their ability to lower blood glucose. Growing recognition of this important gap in our understanding of type 2 DM treatment has created confusion for patients and caregiv-ers. Bridging this gap will be crucial for providing more effective integrative treatment in the future.

Metformin

Metformin is a biguanide that is structurally similar to guanidines that were originally discovered in extracts of Galega officinalis (French lilac). Metformin has been in use since the 1950s, thus making it one of the oldest,

and perhaps most effective, oral hypoglycemic drugs. Although its exact mechanism of action is unclear, met-formin improves insulin sensitivity and reduces hepatic gluconeogenesis.

Metformin is the only diabetes medication shown to reduce cardiovascular mortality (OR, 0.74; 95% CI, 0.62 to 0.89) in systematic reviews,104 and as such should be considered first-line treatment for diabetes.

DosageThe typical dose range is 500 to 1000 mg twice daily.

PrecautionsOther than mild occasional nausea and diarrhea, the only drawback of metformin use is impaired vitamin B12 absorp-tion in the terminal ileum, which may lead to vitamin B12 deficiency.105 Metformin may also cause lactic acidosis in patients with renal insufficiency or alcoholism.

Sulfonylureas

Sulfonylureas increase insulin secretion by pancreatic beta cells by binding to membrane channels. Sulfonyl-ureas drugs have also been used for several decades but do not appear to improve cardiovascular outcomes. The use of sulfonylureas is limited by their potential to cause weight gain and association with more frequent hypogly-cemic episodes, which can lead to arrhythmias and cardiac ischemia.106 A systematic review found that glyburide was almost twice as likely as other sulfonylureas to cause hypoglycemia; however, cardiovascular outcomes were identical for all drugs in this class.107 Patients using sul-fonylureas and metformin in combination are reportedly at greater risk of cardiovascular mortality than patients using metformin alone.108

DosageThe usual dose of glyburide is 2.5 to 10 mg twice daily.

PrecautionsGlyburide may cause hypoglycemia and weight gain.

Thiazolidinedione

Thiazolidinediones increase insulin sensitivity by activat-ing peroxisome proliferator-activated receptor gamma, a nuclear receptor with salutary effects on fatty acid bal-ance, adipocyte differentiation, adiponectin, and other factors involved in glucose and lipid metabolism. The use of rosiglitazone has decreased dramatically since it was found to increase the risk of heart attacks by more than 40% in patients with type 2 DM, possibly because of drug-related increases in LDL or congestive heart failure. Pioglitazone (Actos) is the only drug in this class currently licensed for the treatment of type 2 DM. The impact of pioglitazone on cardiovascular outcomes remains unclear; however, a systematic review did find that it improves glycemic control with a mean reduction in HbA1c levels of 0.58%.



DosageThe dose of pioglitazone is 15 to 30 mg once daily.

PrecautionsThe average weight gain associated with the use of piogli-tazone is 7 lb, and mild edema is commonly noted. A further issue with long-term pioglitazone use is osteoporosis, with a meta-analysis of 10 trials involving 13,715 participants dem-onstrating fracture risk is more than doubled with the use of pioglitazone (OR, 2.23; 95% CI, 1.65 to 3.01).109 Piogli-tazone may increase cardiovascular risk.

Incretins

Incretins are hormones produced in the small intestine during a meal that enter the vasculature and trigger insu-lin release by pancreatic beta cells. The two incretins are glucagon-like peptide (GLP-1) and gastric inhibi-tory peptide (GIP). A newer class of drugs that inhibit dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades GLP-1 and GIP, have demonstrated efficacy in increas-ing insulin and decreasing glucagon levels.

Sitagliptin. Sitagliptin (Januvia) is a dipeptidyl peptidase-4 inhibitor.

DosageThe recommended dose of sitagliptin is 100 mg once daily.

PrecautionsThe only side effects noted in trials are nasopharyngitis and headache; however, the long-term safety of sitagliptin remains unclear because DPP-4 degrades dozens of other enzymes and sitagliptin has not been evaluated in long-term trials. The impact of sitagliptin on cardiovascular events and mortality remains unclear; however, meta-analyses indicate that the use of sitagliptin is associated with HbA1c reduc-tions by 0.7%.110

Exenatide and Liraglutide. Exenatide (Byetta) and Liraglutide (Victoza) are GLP-1 analogues. In comparison trials with insulin and other oral hypoglycemic, exenatide and liraglutide have been shown to reduce HbA1c by approximately 1.0% without causing hypoglycemia or weight gain.111 Liraglutide has also been approved for weight loss.

DosageThe dose of exenatide is 5 mcg twice daily for 1 month and increased to 10 mcg twice daily as required. A once-weekly injection is available as a 2 mg weekly subcutaneous dose. The dose of liraglutide is 0.6 mg subcutaneous injection daily for 1 week and then increased to 1.2 mg daily.

PrecautionsReported side effects include diarrhea, nausea, and vomit-ing. Cases of pancreatitis have been reported. Data regard-ing cardiovascular outcomes are not currently available.

Insulin, sulfonylureas, and thiazolidinedione all cause weight gain. Metformin, incretins, and sodium-glucose cotransporter 2 inhibitors are weight neutral or can help with weight loss.

Sodium-Glucose Cotransporter 2 Inhibitors

This new class of medicines inhibits the reabsorption of glucose in the kidney, thereby encouraging the excretion of glucose via the urine. Sodium-glucose cotransporter 2 inhibitors have been found to reduce HbA1c levels by 0.5 to 0.8% and result in mild weight loss.79

Dosage• Dapagliflozin(Farxiga); 5–10 mg by mouth every

morning.• Canagliflozin(Invokana); 100–300 mg before breakfast.• Empagliflozin(Jardiance); 10–25 mg by mouth every

morning.

PrecautionsSodium-glucose cotransporter 2 inhibitors may increase the risk of lower urinary tract infections and should be avoided in patients with a GFR < 45.

Insulin

Although insulin administration can be lifesaving, insu-lin is a proinflammatory hormone. Every effort should be made to optimize glycemic control; however, it is prob-ably best to use the lowest possible doses of exogenous insulin to achieve this goal. Insulin-dependent patients with type 2 DM can often greatly reduce their dose requirements by following an integrative treatment pro-tocol, as described in this chapter.

One important mechanism underlying the risk of type 2 DM is stimulation of insulin-like growth fac-tor-1 (IGF-1) and other growth hormones. IGF-1 levels predict cancer risk, with the first indication that insulin users may be at increased risk of cancer pub-lished in 1967.112 For reasons that are unclear, patients with type 2 DM are at a 20% increased risk of breast cancer113 and a 30% increased risk of colon cancer.114 Research indicates glargine, a long-acting insulin ana-logue, may be more carcinogenic due to greater stim-ulation of IGF-1 compared to other types of insulin. The hope is that the International Study of Insulin and Cancer, funded by Sanofi-Aventis (the makers of glargine), will clarify this issue. Many insulin protocols, regimens, and analogues are available; however, their use is beyond the scope of this chapter. Practitioners should be aware that, although these regimens may allow patients to take their insulin in a more convenient or practical manner, there is a lack of evidence dem-onstrating any approach is superior to another. Short-acting insulin analogues are commonly used; however, meta-analyses indicate these therapies do not provide any advantage over regular human insulin.115 Similarly, there is no evidence to suggest the long-acting insulin analogues, glargine and detemir, are superior to regu-lar insulin.116 Continuous infusion pumps represent a



newer technology that may be superior; however, their benefit has been demonstrated only among patients with type 1 DM.117

Other Drugs That Improve Outcomes

Angiotensin-Converting Enzyme Inhibitors. ACE inhibitors have been shown to have efficacy in preventing and treating type 2 diabetes. Accordingly, the integration between seemingly disparate physiological systems may have a powerful impact on health and disease. The precise mechanisms underlying the effect of the renin-angiotensin system on glucose metabolism remain unclear; however, multiple lines of evidence exist. Angiotensin II is known to mediate vasoconstriction and hypoperfusion of skeletal muscle and pancreatic islets. Angiotensin II also appears to affect insulin signaling and glucose transport by mechanisms that have yet to be elucidated. In a systematic review of 13 trials involving 93,451 patients with hypertension, the use ACE inhibitors reduced the risk of incident type 2 DM by an impressive 26%.118 A number of ACE inhibitors are available, with ramipril being the most widely studied at a recommended dose of 2.5 to 10 mg once daily.

Statins. Statins are universally recommended for patients with type 2 DM; however, their effectiveness in treating type 2 DM is increasingly complicated. As a drug class, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors are known to improve lipid parameters. However, the clear cardiovascular benefits of statins are more strongly associated with antiinflammatory effects. The absolute risk reduction observed with statins is compelling in people who have already had a cardiovascular event; however, the effectiveness of statins is limited in patients who have not. Patients with type 2 DM fall somewhere in between these two patient populations, with the higher baseline vascular risk among patients with diabetes making statin therapy more appropriate.119

Red yeast rice is a natural source of several statin com-pounds and may represent a reasonable alternative for patients who are unable to tolerate or do not wish to use a statin drug.

Unfortunately, recent evidence indicates some statins increase the risk of type 2 DM. In a meta-analysis

of 13 trials involving 91,140 adults, the overall increase in type 2 DM risk was 9% (95% CI, 1.02 to 1.17).120 Subgroup analysis revealed that different statins have very different effects. Simvastatin, atorvastatin, and rosuvastatin increased the risk of type 2 DM, whereas pravastatin reduced the risk.121 This finding indi-cates pravastatin may be a more appropriate choice in patients with type 2 DM until this issue has been resolved. The recommended dose of pravastatin for the treatment of type 2 diabetes is 20 to 80 mg once daily.

Bariatric SurgeryVarious surgical procedures can induce weight loss by resecting, tightening, shrinking, or bypassing the stom-ach and upper digestive tract. These forms of so-called bariatric surgery lead to profound weight loss and may be the most important advance in the treatment of type 2 DM in decades. Although surgery is not the most philo-sophically appealing solution to the worldwide epidemic of type 2 DM and other metabolic diseases related to obesity, it is increasingly recognized by governments and insurers worldwide.

In a review of 103 clinical trial treatment arms involv-ing 3188 patients with type 2 DM, 78% had complete resolution of clinical and laboratory manifestations of diabetes postoperatively, with significant improve-ments observed in 87% of patients with a reported average weight loss of 38.5 kg.122 Long-term reduc-tions in all-cause morbidity and mortality are increas-ingly reported.

Short-term complications include gastric dumping syndrome, hernias, wound infections, and pneumonia. The most important long-term consideration following bariatric surgery is nutrient malabsorption.

Deficiencies of vitamins A, C, D, K, and B12, and folate, iron, selenium, calcium, zinc, and copper should be expected following bariatric surgery.123 All patients who have undergone bariatric surgery should take a daily multivitamin and multimineral supplement. Ane-mia, hyperparathyroidism, and peripheral neuropathy are common postoperatively. Patients who report vague symptoms following bariatric surgery should be evaluated for nutrient deficiency and reminded of the importance of supplementation.

PREVENTION PRESCRIPTION

• Reducestress.• Obtain6to8hoursofrestfulsleeppernight.• Eatalow-glycemicMediterraneandietthat

includes whole grains, vegetable protein, veg-etables, and some fruit, coffee, and moderate alcohol.

• Practicedailyexercise,aerobicorresistance.

• Manageweightandtreatobesity.• Avoidairpollutionbymaintainingasafedis-

tance from high-traffic roads at work and home.• Practiceaformofmindfulnessormeditation.• Treatprediabeteswithaggressivelifestyleinter-

vention and consider metformin 500 to 1000 mg twice daily.



Key Web Resources

Fooducate helps track food with the goal of weight loss. http://www.fooducate.com/

Glooko. This app allows patients to download blood sugar readings and keep a log based on nutrition and medica-tions used.

https://www.glooko.com/

Myfitnesspal. Monitors activity and allows user to set weight loss goals.

https://www.myfitnesspal.com/

Glycemic Index Foundation: Provides eating plans that help control diabetes and lower serum triglyceride levels.

http://www.gisymbol.com/

Diabetes Connect: A community website for the education and discussion of diabetes care.

http://www.diabeticconnect.com/

National Center for Complementary and Integrative Health: Information about an integrative approach to diabetes.

https://nccih.nih.gov/health/diabetes

THERAPEUTIC REVIEW

LIFESTYLE• Consider referral to a comprehensive lifestyle

program if available.

EXERCISE• Encourage daily aerobic or resistance exercise.

DIET• Low-glycemic diet and moderate carbohydrate

reduction.

• Avoidance of sugar-sweetened beverages and juices.

• Consumption of more lentils, beans, pulses and soy, chia and other whole grains, onions and green leafy vegetables, almonds, walnuts, and other nuts.

• Moderate coffee and wine consumption.

MIND-BODY THERAPY• Ask about and treat disordered sleep, stress, anxiety,

and depression.• Discuss stress reduction options and facilitate the

chosen modality.

SUPPLEMENTS• Alpha-lipoic acid: 50 to 100 mg daily.

• Chromium: 200 to 1000 mcg daily.

• Benfotiamine: 350 mg with meals.

• Omega-3 fatty acids: 1 to 4 g daily.

• L-Carnitine: 500 to 1000 mg three times daily.

• Magnesium: 200 to 500 mg daily.

• Vitamin K: 100 mcg daily (caution with warfarin).

BOTANICALS• Cinnamon: 1 to 5 g ground bark with meals or

equivalent extract.

• Fenugreek (Trigonella foenum-graecum): 30 g seed powder or equivalent extract with meals.

• Touchi, water extract (soy) 0.3 g in tea daily.

• Marine collagen peptides: 13 g daily.

• Silymarin: 200 g daily.

• Ivy gourd (Coccinia indica): 15 g powdered dried leaves or equivalent extract.

• Salacia reticulate (kothala himbutu): premanufactured tea daily.

• Gynostemma pentaphylum: 6 g in tea daily.

PHARMACEUTICALS• Metformin: 500 to 1000 mg twice daily.

• Add other drug classes as required to achieve opti-mal glycosylated hemoglobin levels.

SURGERY• Bariatric surgery for morbidly obese

patients.

AA 1

AA 1

AA 1

AA 1

AA 1

AA 1

BB 1

AA 1

BB 22

BB 1

C 1

AAAA 22

BB 22

AA 1

BB 1

BB 1

BB 1

BB 1

BB 22

22C

22C

AAAA 22

AA 33

ACKNOWLEDGMENT

The author would like to acknowledge Richard Nahas, MD, the author of this chapter in the previous edition, because some of the material from the previous edition has been used in this chapter.

REFERENCESReferences are available online at ExpertConsult.com.


http://www.fooducate.com/

https://www.glooko.com/

https://www.myfitnesspal.com/

http://www.gisymbol.com/

http://www.diabeticconnect.com/

https://nccih.nih.gov/health/diabetes

http://ExpertConsult.com

346.e1

REFERENCES 1. WHO: Diabetes Programme: http://www.who.int/diabetes/en/.

Accessed May 2015. 2. Diabetes Atlas: http://www.idf.org/diabetesatlas. Accessed May

2015. 3. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y,

Albright AL, Gregg EW: Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012, JAMA 312(12):1218–1226, 2014 Sep.

4. Hackethal V: 2 in 5 American adults will develop diabetes, Med-scape medical news: http://www.medscape.com/viewarticle/829833. Accessed May 2015.

5. Shoback: In Gardner D, Dolores G, editors: Greenspan’s basic & clinical endocrinology, ed 9, New York, 2011, McGraw-Hill Medi-cal, Chapter 17.

6. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM: Williams textbook of endocrinology, 12th ed, Philadelphia, Elsevier/Saunders, pp. 1371–1435.

7. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO: Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002, Dia-betes Care 28(7):1599, 2005.

8. Canadian Diabetes Association: An economic tsunami: the cost of diabetes in canada, Toronto, 2009, Canadian diabetes association Toronto.

9. Narayan KM, Thompson TJ, Boyle JP: The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males, Health Care Manag Sci 223–227, 1999.

10. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK: Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physi-cal inactivity, and high-calorie diet in healthy subjects, J Clin Endocrinol Metab 96(2):447–453, Feb 2011.

11. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Atherosclerosis Risk in Communities Study, Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in com-munities study, Diabetes 52(7):1799, 2003.

12. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C- reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA 286(3):327, 2001.

13. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA: High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes, Diabetes 51(2):455, 2002.

14. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu: Circulating adiponectin levels are associated with better glycemic con-trol, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes, J Clin Endocrinol Metab 90(8):4542, 2005.

15. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsu-linemia, J Clin Endocrinol Metab 86(5):1930, 2001.

16. Unger RH, Orci L: Paracrinology of islets and the paracrinopathy of diabetes, Proc Natl Acad Sci U S A 107(37):16009–16012, Sep 14 2010.

17. Wheeler E, Barroso I: Genome-wide association studies and type 2 diabetes, Brief Funct Genomics 10(2):52–60, Mar 2011.

18. Billings LK, Florez JC: The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 1212:59–77, 2010 Nov.

19. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes, Nature 445(7130):881–885, Feb 22 2007.

20. Lindgren CM, McCarthy MI: Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity, Nat Clin Pract Endocrinol Metab 4(3):156–163, Mar 2008.

21. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E: Arsenic exposure and prevalence of type 2 diabetes in US adults, JAMA 300(7):814, 2008.

22. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, Melzer D: Association of urinary bisphenol A con-centration with medical disorders and laboratory abnormalities in adults, JAMA 300(11):1303, 2008.

23. Montgomery MP, Kamel F, Saldana TM, Alavanja MC, Sandler DP: Incident diabetes and pesticide exposure among licensed pes-ticide applicators: agricultural Health Study, 1993-2003, Am J Epidemiol 167(10):1235, 2008.

24. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, Finnish Diabetes Prevention Study Group, N Engl J Med 344(18):1343, 2001.

25. AU Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the inci-dence of type 2 diabetes with lifestyle intervention or metformin, Diabetes Prevention Program Research Group, N Engl J Med 346(6):393, 2002.

26. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study, Diabetes Care 20(4):537, 1997.

27. Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, Fukunaga R, Bandai Y, Tajima N, Nakamura Y, Ito M, Zensharen Study for Prevention of Lifestyle Diseases Group: Lifestyle modi-fication and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial, Arch Intern Med 171(15):1352, 2011.

28. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J: Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis, JAMA 298(22):2654, 2007.

29. Wannamethee SG, Shaper AG, Perry IJ: Smoking as a modifi-able risk factor for type 2 diabetes in middle-aged men, British Regional Heart Study, Diabetes Care 24(9):1590, 2001.

30. Hu FB, Stampfer MJ, Solomon C: Physical activity and risk for cardiovascular events in diabetic women, Ann Intern Med 134:96–105, 2001.

31. Gregg EW, Gerzoff RB, Caspersen CJ: Relationship of walk-ing to mortality among US adults with diabetes, Arch Intern Med 163:1440–1447, 2003.

32. Hu G, Jousilahti P, Barengo NC: Physical activity, cardiovascu-lar risk factors, and mortality among Finnish adults with diabetes, Diabetes Care 28:799–805, 2005.

33. Gordon BA, Benson AC, Bird SR, Fraser SF: Resistance training improves metabolic health in type 2 diabetes: a systematic review, Diabetes Res Clin Prac 83:157–175, 2009.

34. Aljasir B, Bryson M, Al-Shehri B: Yoga practice for the manage-ment of type II diabetes mellitus in adults: a systematic review, Evid Based Complement Alternat Med 7:399–408, 2010.

35. Gordon L, Morrison EY, McGrowder DA: Changes in clinical and metabolic parameters after exercise therapy in patients with type 2 diabetes, Arch Med Sci 4:427–437, 2008.

36. Standards of medical care in diabetes–2013: American Diabetes Association Diabetes Care, 36(Suppl 1):S11, 2013.

37. Pastors JG, Warshaw H, Daly A, et al.: The evidence for the effec-tiveness of medical nutrition therapy in diabetes management, Diabetes Care 25:608e13, 2002.

38. Imai S, Kozai H, Matsuda M, et al.: Intervention with delivery of diabetic meals improves glycemic control in patients with type 2 diabetes mellitus, J Clin Biochem Nutr 42(1):59–63, 2008.

39. Pi-Sunyer FX, Maggio CA, McCarron DA, et al.: Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes, Diabetes Care 22:191e7, 1999.

40. Franz MJ, Monk A, Barry B, et al.: Effectiveness of medical nutri-tion therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial, J Am Diet Assoc 95:1009e17, 1995.

41. Gaetke L, Stuart M, Truszczynska H: A single nutrition counsel-ing session with a registered dietitian improves short-term clinical outcomes for rural Kentucky patients with chronic diseases, J Am Diet Assoc 106:109e12, 2006.

42. Brand-Miller J, Hayne S, Petocz P, et al.: Low glycemic index diets in the management of diabetes: a meta-analysis of random-ized controlled trials, Diabetes Care 26:2261e7, 2003.

43. Anderson JW, Randles KM, Kendall CW, et al.: Carbohydrate and fiber recommendations for individuals with diabetes: a quan-titative assessment and meta-analysis of the evidence, J Am Coll Nutr 23:5e17, 2004.


http://www.who.int/diabetes/en/

http://www.idf.org/diabetesatlas

http://www.medscape.com/viewarticle/829833

346.e2 References

44. Sievenpiper JL, Kendall CWC, Esfahani A, et al.: Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes, Diabetologia 52:1479e95, 2009.

45. Jang Y, Lee JH, Kim OY, et al.: Consumption of whole grain and legume powder reduces insulin demand, lipid peroxidation, and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial, Arterioscler Thromb Vasc Biol 12:2065e71, 2001.

46. Bazzano LA, Thompson AM, Tees MT, et al.: Non-soy legume consumption lowers cholesterol levels: a meta-analysis of ran-domized controlled trials, Nutr Metab Cardiovasc Dis 2:94e103, 2011.

47. Jenkins DJ, Kendall CW, Banach MS, et al.: Nuts as a replacement for carbohydrates in the diabetic diet, Diabetes Care 34:1706e11, 2011.

48. Cohen AE, Johnston CS: Almond ingestion at mealtime reduces postprandial glycemia and chronic ingestion reduces hemoglobin A1C in individuals with well-controlled type 2 diabetes mellitus, Metabolism 6:1312e7, 2011.

49. Li S-C, Liu Y-H, Liu J-F, et al.: Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus, Metabolism 60:474e9, 2011.

50. Mann JI, De Leeuw I, Hermansen K, et al.: Evidence-based nutri-tional approaches to the treatment and prevention of diabetes mellitus, Nutr Metab Cardiovasc Dis 14:373e94, 2004.

51. Barnard ND, Cohen J, Jenkins DJA, et al.: A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabe-tes: a randomized, controlled, 74-wk clinical trial, Am J Clin Nutr 89:1588Se96S, 2009.

52. Kahleova H, Matoulek M, Malinska H, et al.: Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes, Diabet Med 28:549e59, 2011.

53. Jang Y, Lee JH, Kim OY, et al.: Consumption of whole grain and legume powder reduces insulin demand, lipid peroxidation, and plasma homocysteine concentrations in patients with coronary artery disease: randomized controlled clinical trial, Arterioscler Thromb Vasc Biol 12:2065e71, 2001.

54. Howard AA, Arnsten JH, Gourevitch MN: Effect of alcohol con-sumption on diabetes mellitus: a systematic review, Ann Intern Med 140(3):211, 2004.

55. Lovejoy JC, Smith SR, Champagne CM, Most MM, Lefevre M, DeLany JP, Denkins YM, Rood JC, Veldhuis J, Bray GA: Effects of diets enriched in saturated (palmitic), monounsaturated (oleic), or trans (elaidic) fatty acids on insulin sensitivity and substrate oxi-dation in healthy adults, Diabetes Care 25(8):1283, 2002.

56. Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, Petrizzo M, Saccomanno F, Beneduce F, Ceriello A, Giugliano D: Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial, Ann Intern Med 151(5):306, 2009.

57. Esposito K, Maiorino MI, Petrizzo M, Bellastella G, Giugliano D: The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial, Diabetes Care 37(7):1824–1830, 2014 Jul. Epub 2014 Apr 10.

58. Dong JY, Xun P, He K, Qin LQ: Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies, Dia-betes Care 34(9):2116–2122, 2011 Sep.

59. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, Grobbee DE, Batty D, Woodward M: Coffee, decaf-feinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis, Arch Intern Med 169(22):2053, 2009.

60. Davidson RJ, Lutz A: Buddha’s brain: neuroplasticity and medita-tion, IEEE Signal. Process Mag. 25:171–174, 2008.

61. Alam R, Sturt J, Lall R, Winkley K: An updated meta-analysis to assess the effectiveness of psychological interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on psychological status, Patient Educ Couns 75:25e36, 2009.

62. Delamater AM, Jacobson AM, Anderson B, et al.: Psychosocial therapies in diabetes: report of the Psychosocial Therapies Work-ing Group, Diabetes Care 24:1286e92, 2001.

63. Gary T, Genkinger J, Guallar E: Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes, Diabe-tes Educ 29:488–501, 2003.

64. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA: Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis, Diabetes Care 33(2):414–420, 2010 Feb. Epub 2009 Nov 12.

65. Kuriyan R, Rajendran R, Bantwal G, Kurpad AV: Effect of sup-plementation of Coccinia cordifolia extract on newly detected dia-betic patients, Diabetes Care 31:216–220, 2008.

66. Jayawardena MH, de Alwis NM, Hettigoda V: A double blind randomised placebo controlled cross over study of a herbal prepa-ration containing Salacia reticulata in the treatment of type 2 dia-betes, J Ethnopharmacol 87:215–218, 2005.

67. Fujita H, Yamagami T, Ohshima K: Long-term ingestion of a fermented soybean-derived Touchi extract with alpha-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes, J Nutr 131:2105–2108, 2001.

68. Huyen VTT, Phan DV, Thang P: Antidiabetic effect of gyn-ostemma pentaphyllum tea in randomly assigned type 2 diabetic patients, Horm Metab Res 42:353–357, 2010.

69. Zhu CF, Li GZ, Peng HB: Treatment with marine collagen pep-tides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus, Appl Physiol Nutr Metab 35:797–804, 2010.

70. Hussain SA: Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes, J Med Food 10:543–547, 2007.

71. Huseini HF, Larijani B, Heshmat R: The efficacy of Silybum mari-anum (L.) Gaertn. (silymarin) in the treatment of type II diabe-tes: a randomized, double-blind, placebo-controlled, clinical trial, Phytother Res 20:1036–1039, 2006.

72. Huseini HF, Darvishzadeh F, Heshmat R: The clinical investiga-tion of Citrullus colocynthis schrad (L.) fruit in treatment of type II diabetic patients: a randomized, double blind, placebo-controlled clinical trial, Phytother Res 23:1186–1189, 2009.

73. Crawford P: Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial, J Am Board Fam Med 22:507–551, 2009.

74. Akilen R, Tsiami A, Devendra D, Robinson N: Glycated hae-moglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a random-ized, placebo-controlled, double-blind clinical trial, Diabet Med 27:1159–1167, 2010.

75. Leach MJ, Kumar S: Cinnamon for diabetes mellitus, Cochrane Database Syst Rev 9:CD007170, 2012.

76. Davis PA, Yokoyama W: Cinnamon intake lowers fasting blood glucose: meta-analysis, J Med Food 14(9):884, 2011.

77. Lu FR, Shen L, Qin Y: Clinical observation on trigonellafoenum-grae-cum L. total saponins in combination with sulfonylureas in the treat-ment of type 2 diabetes mellitus, Chin J Integr Med 14:56–60, 2008.

78. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM: Systematic review: vitamin D and cardiometabolic outcomes, Ann Intern Med 152(5):307, 2010.

79. Van Gaal L, Scheen A: Weight Management in Type 2 Diabetes: current and Emerging Approaches to Treatment, Diabetes Care 38:1161–1172, 2015.

80. Huseini HF, Darvishzadeh F, Heshmat R: The clinical investiga-tion of Citrullus colocynthis schrad (L.) fruit in treatment of type II diabetic patients: a randomized, double blind, placebo-controlled clinical trial,, Phytother Res 23:1186–1189, 2009.

81. Song Y, He K, Levitan EB, et al.: Effects of oral magnesium sup-plementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials, Diabet Med 23:1050–1056, 2006.

82. Larsson SC, Wolk A: Magnesium intake and risk of type 2 diabe-tes: a meta-analysis, J Intern Med 262:208–214, 2007.

83. Song Y, Cook NR, Albert CM, et al.: Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial, Am J Clin Nutr 90:429–437, 2009.

84. Belch J, MacCuish A, Campbell I, et al.: The prevention of pro-gression of arterial disease and diabetes (POPADAD) trial: facto-rial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial dis-ease, BMJ 337:a1840, 2008.


346.e3References

85. Fenercioglu AK, Saler T, Genc E, et al.: The effects of polyphe-nol-containing antioxidants on oxidative stress and lipid peroxida-tion in type 2 diabetes mellitus without complications, J Endocrinol Invest 33:118–124, 2010.

86. Kataja-Tuomola M, Sundell JR, Mannisto S, et al.: Effect of alphatocopherol and beta-carotene supplementation on the inci-dence of type 2 diabetes, Diabetologia 2008; 51:47–53, 2008.

87. Winterbone MS, Sampson MJ: Pro-oxidant effect of alpha-tocopherol in patients with type 2 diabetes after an oral glucose tolerance test: a randomised controlled trial, Cardiovasc Diabetol 6:8, 2007.

88. Devaraj S, Jialal I: Failure of vitamin E in clinical trials: is gam-matocopherol the answer? Nutr Rev 63:290–293, 2005.

89. Wu JHY, Ward NC, Indrawan AP, et al.: Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes, Clin Chem 53:511–519, 2007.

90. Ward NC, Wu JHY, Clarke MW, et al.: The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a random-ized, doubleblind, placebo-controlled trial, J Hypertens 25:227–234, 2007.

91. Clarke MW, Ward NC, Wu JHY, et al.: Supplementation with mixed tocopherols increases serum and blood cell gamma-tocoph-erol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes, Am J Clin Nutr 83:95–102, 2006.

92. Milman U, Blum S, Shapira C, et al.: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged indi-viduals with both type 2 diabetes mellitus and the haptoglobin 2–2 genotype: a prospective double-blinded clinical trial, Arterioscler Thromb Vasc Biol 28:341–347, 2008.

93. Gonzalez-Ortiz M, Hernandez-Gonzalez SO, Hernandez-Salazar E, Martinez-Abundis E: Effect of oral l-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients, Ann Nutr Metab 52:335–338, 2008.

94. Galvano F, Li Volti G, Malaguarnera M, et al.: Effects of sim-vastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus, Expert Opin Pharmaco-ther 10:1875–1882, 2009.

95. Stirban A, Negrean M, Stratmann B, et al.: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes, Diabetes Care 29:2064–2071, 2006.

96. Nikolić A, Kacar A, Lavrnić D, et al.: The effect of benfotiamine in the therapy of diabetic polyneuropathy, Srp Arh Celok Lek 137:594–600, 2009 [in Serbian].

97. Stracke H, Gaus W, Achenbach U, et al.: Benfotiamine in dia-betic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study, Exp Clin Endocrinol Diabe-tes 116:600–605, 2008.

98. Alkhalaf A, Klooster A, van Oeveren W, et al.: A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy, Diabetes Care 33:1598–1601, 2010.

99. Rabbani N, Alam SS, Riaz S, et al.: High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a ran-domised, double-blind placebo-controlled pilot study, Diabetologia 52:208–212, 2009.

100. Beulens JWJ, van der ADL, Grobbee DE, et al.: Dietary phyl-loquinone and menaquinones intakes and risk of type 2 diabetes, Diabetes Care 33:1699–1705, 2010.

101. Ford SK, Moll S: Vitamin K supplementation to decrease vari-ability of international normalized ratio in patients on vitamin K antagonists: a literature review, Curr Opin Hematol 15:504–508, 2008.

102. Stranges S, Marshall JR, Natarajan R, et al.: Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial, Ann Intern Med 147:217–223, 2007.

103 House AA, Eliasziw M, Cattran DC, et al.: Effect of B-vitamin ther-apy on progression of diabetic nephropathy: a randomiz controlled trial, JAMA 303(16):1603-1609, 2010.


Documents

Chapter 33 - Diabetes Mellitus - d2ogjlfjkptkow.cloudfront.net · Diabetes is largely preventable. The principles of preven - tative management apply a holistic therapeutic approach